Research On The Performance Evaluation Of China's Centralized Drug Procurement System From The Perspective Of Accessibility

In order to fully ensure drug supply,reduce the burden of drug use on patients,and put an end to the long-standing problem of commercial corruption in drug production and hospitals,China formally formulated and implemented the centralized drug procurement system since 2000.In the past 20 years,the centralized drug procurement system has played an important role in controlling drug costs,reducing drug prices,ensuring drug supply,promoting drug safety,and improving drug circulation environment.It is difficult to make an empirical study on the performance of centralized drug procurement system in China due to its large number and complex structure.Drug accessibility provides an operational perspective and reduces the complexity of evaluation.On the basis of literature research,domestic and foreign research results,the status quo of China's centralized drug procurement system,and the analysis of the practical problems of drug accessibility in China,this paper "coupled" the system of centralized drug procurement with the connotation of drug accessibility,and clarified the basic dimensions of evaluation.Through questionnaires and interviews,on the basis of determining the evaluation dimensions,the indicators were selected through expert scoring and feasibility analysis.Through the analytic hierarchy process(AHP)and CRITIC method,subjective and objective weighting is carried out,and the indicator system is formed.Through empirical research,the authoritative data published by National Administrative Bureau of the State Owned Property of the People's Republic of China(NABS)were brought into the evaluation system,and it was found that: from 2015 to 2018,the proportion of drug expenses in China declined steadily,but the sales expenses of enterprises increased year by year,indicating that the burden of drug use of the people was constantly reduced,but there was still large space for drug expenses to fall.The low efficiency of drug purchase and sale transaction and the prominent problem of safe drug use indicate that the drug purchase and sale transaction cycle is long,poor system performance,and the centralized drug purchase system is insufficient to ensure the quality and safety of drugs and promote rational drug use.The scale of the pharmaceutical industry and the purchase and sale market has been expanding year by year,but there is monopoly risks in the market.Based on the results of the empirical study,the paper puts forward some strategies to further improve the centralized drug procurement system in China.First,continue to adhere to the correct system development orientation.Second,we will continue to reduce drug costs,continue to purchase drugs in large quantities,innovate in the practice of centralized drugprocurement,expand the marginal benefits of the system,and ensure that drug prices remain within a reasonable range in the long run.Third,we need to strengthen drug quality management.On the one hand,we need to "intercept the flow" and make sure that the quality of drugs is properly selected.The fourth is to reduce the transaction cost and improve the efficiency of drug transaction,and at the same time to use institutional leverage to adjust the allocation of market resources and improve the level of drug supply.Fifth,we will strengthen market management and services,crack down on illegal drug purchases and sales,and protect the legitimate rights and interests of both buyers and sellers.